Fewer than 20 GCC centres perform the kidney biopsy IgA nephropathy diagnosis requires, gating an 8,000-12,000 patient market.

Targeted-release budesonide (Tarpeyo), which cut UPCR by 31% in NefIgArd, is SFDA-registered and under 2023 MOH UAE registration, with GCC nephrology centres beginning to prescribe. Sparsentan (Filspari), which cut UPCR by 49.8% in PROTECT, carries a GCC registration timeline running 18 to 24 months behind its 2023 FDA approval and remains available only through selected compassionate use, with physician familiarity outside academic centres low. Neither agent is yet listed on a GCC-wide formulary as of 2024; access decisions are made hospital by hospital, with the private hospital market representing the fastest channel.

The larger constraint on the GCC IgAN opportunity is diagnostic, not regulatory: kidney biopsy, required for definitive diagnosis, is performed at fewer than 20 centres across the six GCC states, mostly by nephrologists rather than interventional radiology. IgAN is estimated at 15-20% of proteinuric CKD in the region, but the GCC's 20-25% adult diabetes prevalence means diabetic nephropathy accounts for roughly 60% of CKD referrals, crowding out non-diabetic proteinuric patients from the IgAN screening pathway. Estimated GCC IgAN prevalence runs 8,000 to 12,000 patients, and UPCR-based treatment-eligibility criteria are still forming.

Diabetic-nephropathy crowding, not drug access, keeps most IgAN patients undiagnosed.

Five questions this report answers:

Q1 - Which GCC nephrology centres and private hospitals are the fastest access channel for budesonide and sparsentan?

Q2 - How does the kidney-biopsy capacity constraint limit the identified IgAN patient pool in GCC?

Q3 - What UPCR-based treatment-eligibility criteria are forming across GCC nephrology practice?

Q4 - How do specialist-centre access and the biopsy bottleneck shape the addressable GCC IgAN market?

Q5 - How does the diabetes-dominated CKD referral pattern crowd out non-diabetic IgAN patients?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#IgANephropathy #GCC #Nephrology #Sparsentan #Budesonide #MarketAccess

Live report page:  https://axlrx.ai/iga-nephropathy/gcc/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-   hello@axlrx.ai

Web-   https://axlrx.ai/